Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.

When science, humanity and purpose connect, lives can be transformed.

**SCIENCE**

Pushing the boundaries of what’s possible

**HUMANITY**

A deep caring for human life

**PURPOSE**

Advancing science for life
Pamela Chang is a survivor. The 73-year-old has a long, complex history of heart disease, but to her family, she is a pillar of strength. After immigrating to the United States from Jamaica, she worked as a nurse for 40 years and took on multiple shifts to ensure her children, including our Chief Diversity, Equity and Inclusion Officer Camille Chang Gilmore, could go to college. Over the years, Pamela has been treated with several coronary therapies from Boston Scientific. But recently, after experiencing painful swelling in her right leg, physicians discovered blockages there. Pamela underwent a peripheral vascular procedure, in which doctors used Boston Scientific technology to open the blood vessels in her lower leg and foot. Now, once again, Pamela is back enjoying a full life with her family.

At Boston Scientific, our 2020 story unfolded through the experiences of health care professionals, patients, our employees and communities during a global pandemic. As we saw humanity tested, our people stepped up in unforeseen ways to work safely as they served customers and navigated the complexities of delivering critical solutions to patients everywhere. In a year of reckoning, we were compelled to act — inside and outside the company — as we came face to face with deep social unrest, inequities and health disparities. Our people cared for one another and our communities in ways never imagined as they stayed true to our values and focused on addressing the needs of patients.

Pamela Chang is one of those patients. Her experience exemplifies why we are dedicated to advancing science for life and why — when science, humanity and purpose come together — we can change and save lives.

“We’re focused on delivering meaningful innovations and making sure everyone who needs quality care gets it. That objective became very real for my family in 2020. The hard work of people across Boston Scientific saved my mom’s life.”

Camille Chang Gilmore, global chief diversity, equity and inclusion officer, Boston Scientific, and Pamela’s daughter

“I feel much better. I don’t know if I could run a marathon, but I could try!”

Pamela Chang, Boston Scientific patient, and Camille’s mom
Table of Contents

This report has been prepared in accordance with the Global Reporting Initiative guidelines. Unless otherwise indicated, data in the 2020 Performance Report Addendum are as of December 31, 2020, or for the one-year period ending in December 31, 2020, as applicable.
2020 has been a year unlike any we could have imagined. As a society, we confronted COVID-19 and its economic fallout. We watched the pandemic take a disproportionate toll on communities of color, and we saw long-standing inequities and systemic racism painfully exposed. We experienced political unrest as well as the continued devastating effects of climate change. Amid this disruption, Boston Scientific was guided and united by our mission to transform lives through medical solutions that improve the health of patients around the world. Our 38,000 employees were led by our values, and we fulfilled our mission — as a global business and as a global corporate citizen.

2020 taught us that when science, humanity and purpose connect, we can make a meaningful difference in the world. We measure our progress by the ways in which we transform care, invest in our people, advance possibilities, protect the environment and create value responsibly.

In a year without precedent our teams were resilient and agile, and as a result of their hard work our business remains strong. We invested more than $1 billion in research and development and brought to market 69 new products to advance patient care. Our teams conducted 119 clinical studies and pursued opportunities to expand access to health care in emerging markets. We increased our digital investments in customer and patient engagement, medical education, and remote support for clinical trials. Most important, we touched the lives of nearly 30 million patients, took care of one another and supported communities in need.

Responding to COVID-19

Boston Scientific mobilized quickly to protect our employees and support global COVID-19 relief efforts. We helped communities by contributing more than $18 million in aid through monetary and supply donations and by volunteering and providing expertise and resources in engineering and manufacturing. Here are some noteworthy examples of what we accomplished:

- Assembled more than one million face shields and donated them to health care providers.

- Worked with the University of Minnesota Bakken Medical Devices Center and others in the industry to create the Coventor, an emergency resuscitator that can be used when traditional ventilators are not available.
Collaborated with an international coalition of medical experts, clinicians and industry leaders to design and develop the Pneumask™ Face Shield, a reusable full-face mask that was authorized by the Food and Drug Administration (FDA) for use as personal protective equipment in clinical settings.

Tapped our supply chain capabilities to help source and produce parts for commercial ventilators and to enable increased global production of transportable ventilators.

We did all this while making significant changes to our global workforce operations to keep employees, customers and patients safe. Our employees rose to every challenge, and we added resources to support their physical, mental and financial health during this uncertain time.

Building a More Diverse, Equitable and Inclusive Workplace and Society

The challenges of COVID-19 and the racial injustice and social unrest we experienced in 2020 underscore how important it is that we address the root causes of racism and build a more equitable, inclusive society – within Boston Scientific and our communities. In 2020, we made progress against our goals and took the following actions to support diversity, equity and inclusion:

- Expanded on our 2017 diversity and inclusion goals with 3Up by 2023, an initiative to increase representation of multicultural talent and women at the supervisory and managerial levels to 23 percent and 43 percent, respectively.

- Achieved 99+ percent pay equity for gender globally and 99+ percent pay equity for multicultural talent in the United States, including Puerto Rico.

- Announced a $3.5 million multiyear investment to combat racism in the United States, with a focus on advocacy in five areas: community, economic empowerment, education, health care disparities and government policy.

- Through Close the Gap, launched a public service advertising campaign to increase awareness of health disparities and promote resources to help health care providers address them.

- Supported diverse representation among health care professionals through scholarships for Black graduate-level healthcare students.

- Funded primary and secondary school grants to encourage the next generation to achieve in science, technology, engineering and math (STEM).

Our work is guided by core values; they define the culture at Boston Scientific and empower our employees

**CARING**
We act with integrity and compassion to support patients, customers, our communities and each other.

**DIVERSITY**
We embrace diversity and value unique talents, ideas and experiences of our employees.

**GLOBAL COLLABORATION**
We work collaboratively to pursue global opportunities that extend the reach of our medical solutions.

**HIGH PERFORMANCE**
We strive for high performance to benefit our patients, clinicians and shareholders.

**MEANINGFUL INNOVATION**
We foster the creativity to transform new ideas into breakthrough services and solutions that create value for patients, customers and employees.

**WINNING SPIRIT**
We adapt to change and act with speed, agility and accountability to further improve patient care.
I am grateful for the passion and commitment of our global team and proud of the progress we have made. There is much work to be done, but I continue to be optimistic about the future of our world and the future of Boston Scientific. We have a strong pipeline and an extraordinarily talented and caring team that is committed to achieving our mission by sustaining ethical and inclusive business practices. I look forward to continuing our work together to meet the challenges ahead and to build a better and more equitable future for all.

Sincerely,

Mike Mahoney
Chairman, President and CEO
April 15, 2021
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care.

### NET SALES BY PRODUCT CATEGORY

<table>
<thead>
<tr>
<th>Product Category</th>
<th>Net Sales (dollars in millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDSURG</td>
<td>$1,780 million</td>
</tr>
<tr>
<td>UROLOGY + PELVIC HEALTH</td>
<td>$1,286 million</td>
</tr>
<tr>
<td>CARDIAC RHYTHM MANAGEMENT</td>
<td>$1,704 million</td>
</tr>
<tr>
<td>ELECTROPHYSIOLOGY</td>
<td>$287 million</td>
</tr>
<tr>
<td>NEUROMODULATION</td>
<td>$761 million</td>
</tr>
<tr>
<td>INTERVENTIONAL CARDIOLOGY</td>
<td>$2,299 million</td>
</tr>
<tr>
<td>PERIPHERAL INTERVENTIONS</td>
<td>$1,577 million</td>
</tr>
</tbody>
</table>

### NET SALES BY REGION

<table>
<thead>
<tr>
<th>Region</th>
<th>Net Sales (dollars in millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>$5,508</td>
</tr>
<tr>
<td>EMEA (Europe, Middle East and Africa)</td>
<td>2,097</td>
</tr>
<tr>
<td>APAC (Asia-Pacific)</td>
<td>1,781</td>
</tr>
<tr>
<td>LACA (Latin America and Canada)</td>
<td>307</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>9,913</strong></td>
</tr>
</tbody>
</table>

1. We have three reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices). We have included the results of BTG’s Interventional Medicine business in our Peripheral Interventions operating segment since the date of acquisition.  
2. As part of our acquisition of BTG, we acquired a specialty pharmaceuticals business (Specialty Pharmaceuticals), a stand-alone operating segment presented alongside our Medical Device reportable segments. On March 1, 2021, we completed the sale of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L. and SERB SAS, affiliates of SERB, for a purchase price of $800 million.
Boston Scientific collaborates with health care professionals to develop meaningful innovations that help more people live longer, healthier lives. We invest in bringing new products to large, high-growth markets while building our unique pipeline of technologies to expand our category leadership and address unmet patient needs. Our innovative culture has enabled us to serve approximately 30 million patients annually.

### Meaningful Innovation

Boston Scientific collaborates with health care professionals to develop meaningful innovations that help more people live longer, healthier lives. We invest in bringing new products to large, high-growth markets while building our unique pipeline of technologies to expand our category leadership and address unmet patient needs. Our innovative culture has enabled us to serve approximately 30 million patients annually.

#### BUSINESS SEGMENTS

- **Cardiovascular**
  - Interventional Cardiology
  - Peripheral Interventions
  - Rhythm and Neuro (CRM and EP)
  - Neuromodulation
  - MedSurg

#### BUSINESS UNITS

- **KEY PRODUCTS**
  - Interventional Cardiology:
    - WATCHMAN FLX™ Left Atrial Appendage Closure Device
    - ACURATE neo2™ Aortic Valve System
    - ROTAPRO™ Rotational Atherectomy System
  - Peripheral Interventions:
    - ELUVIA™ Drug-Eluting Vascular Stent System and Ranger™ Drug Coated Balloon
    - TheraSphere™ Y-90 Glass Microspheres
    - AngioJet™ Peripheral Thrombectomy System
    - EkoSonic™ Endovascular System
  - Rhythm and Neuro (CRM and EP):
    - HeartLogic™ Heart Failure Diagnostic
    - LUX-Dx™ Insertable Cardiac Monitor System
    - POLARx™ Cryoablation System
  - Neuromodulation:
    - WaveWriter Alpha™ Spinal Cord Stimulation System
    - Vertiflex™ Procedure, Superion™ Indirect Decompression System
    - Vercise Genus™ Deep Brain Stimulation System
  - MedSurg:
    - EXALT™ Model D Single-use Duodenoscope, SpyGlass™ Discover Digital Catheter
    - AXIOS™ Stent and Electrocautery-Enhanced Delivery System
    - ORISE™ Gel Submucosal Lifting Agent and ORISE™ ProKnife Electrosurgical Knife
  - Urology and Pelvic Health:
    - LithoVue™ Single-Use Digital Flexible Ureteroscope
    - SpaceOAR™ Hydrogel Prostate Spacer
    - SpaceOAR Vue™ Hydrogel Radiopaque Perirectal Spacer
    - Rezūm™ Water Vapor Therapy

---

**BUSINESS SEGMENTS BUSINESS UNITS KEY PRODUCTS**

<table>
<thead>
<tr>
<th>BUSINESS SEGMENTS</th>
<th>BUSINESS UNITS</th>
<th>KEY PRODUCTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>Interventional Cardiology</td>
<td>WATCHMAN FLX™ Left Atrial Appendage Closure Device, ACURATE neo2™ Aortic Valve System, ROTAPRO™ Rotational Atherectomy System</td>
</tr>
<tr>
<td></td>
<td>Rhythm and Neuro (CRM and EP)</td>
<td>HeartLogic™ Heart Failure Diagnostic, LUX-Dx™ Insertable Cardiac Monitor System, POLARx™ Cryoablation System</td>
</tr>
<tr>
<td></td>
<td>Urology and Pelvic Health</td>
<td>LithoVue™ Single-Use Digital Flexible Ureteroscope, SpaceOAR™ Hydrogel Prostate Spacer, SpaceOAR Vue™ Hydrogel Radiopaque Perirectal Spacer, Rezūm™ Water Vapor Therapy</td>
</tr>
</tbody>
</table>
United by our core values, we are dedicated to transforming lives through innovative medical solutions, while also making measurable contributions to the world we share. Here are some highlights.
At Boston Scientific, corporate social responsibility (CSR) underpins all our business practices, and our approach is aligned with the United Nations Sustainable Development Goals (SDGs).

**CSR Strategy and Practices**

Our CSR strategy, material topics and practices are informed by conversations with diverse stakeholders inside and outside the company — locally, nationally and globally. In our collaborations and other business relationships, we work with organizations that share our commitment to better understand and improve environmental, social and economic progress.

In more than 100 countries, our people work with an awareness of the world’s most pressing challenges, including inequity, economic disparity, climate change and environmental protection. Their efforts are supported by:
- Our cross-functional CSR Council.
- Environmental Health and Safety (EH&S) policies.
- Global Council for Inclusion.
- Local, regional and national employee and community programs.

---

### SUSTAINABLE DEVELOPMENT GOALS AND MATERIAL TOPICS

#### TRANSFORMING CARE

**Material topics:**
- Innovative products

#### INVESTING IN OUR PEOPLE

**Material topics:**
- Career, culture and talent
- Diversity, equity and inclusion
- Worker health and safety

#### ADVANCING POSSIBILITIES

**Material topics:**
- Community engagement

#### PROTECTING THE ENVIRONMENT

**Material topics:**
- Environmental impact
- Climate change

#### CREATING VALUE RESPONSIBLY

**Material topics:**
- Governance
- Compliance and ethics
- Sustainable supply chain

The CSR Council includes subject matter experts from throughout the company who help define our CSR strategy and ensure accountability. An executive steering committee oversees the Council and champions sustainable practices across the business. Within this framework, everyone in the company contributes to our social responsibility.

Each year, we participate in several widely recognized environmental-, social- and governance-rating surveys. In 2020, we initiated a climate risk scenario analysis based on the Task Force on Climate-related Financial Disclosures framework.
Our commitment to improving the lives of patients requires high levels of research, quality and innovation in every aspect of our operations.

Boston Scientific teams collaborate across the company and with health care providers and other trusted external experts to design and make solutions for the health care challenges that matter the most. We are inspired by the people who have been helped by our products, and we are driven to serve those who need breakthroughs that have not yet been invented.
Our Approach to Innovative and Quality Products

Boston Scientific product development teams follow a uniform, global approach that combines business, technical and quality processes. This allows us to monitor products over their life cycles, from concept and commercialization through next-generation designs. The data we gather and analyze helps us pursue new solutions that advance standards of care and address unmet customer and patient needs.

We have research and development sites in the United States, the European Union, Costa Rica, India and China. Some of the sites also serve as R&D Centers of Excellence where we identify successful practices and share them across the company to strengthen our overall R&D capability.

Quality and Safety

Our commitment to meaningful innovation is matched by a customer- and patient-centric focus on quality and safety. The work and expertise of Boston Scientific global quality and safety teams is supported by:

- **Quality system training** for all employees.
- **A companywide plan** that prioritizes quality improvement projects and leads to higher quality products and better patient outcomes.

SUSTAINABLE DEVELOPMENT GOALS:

A global quality system that integrates customer feedback and regulatory requirements into our processes.

The Boston Scientific Best4 quality strategy for delivering industry-leading culture, compliance, performance and agility.

Katie Crawford helps lead global processes that ensure quality and safety are incorporated into everything we do.

“The global reach of our quality system is critical. Boston Scientific employees everywhere know they share responsibility for the quality and safety of our products. Each site has a comprehensive system for maintaining quality, which gives us agility in meeting new requirements such as the European Union Medical Device Regulation.”

Katie Crawford, manager, Quality Systems
To ensure the safety and efficacy of our new technologies and tools, we follow a global design controls process that incorporates risk management and usability engineering. At every stage of development, our teams focus on the patients who will benefit from their efforts. This includes assessing component and device materials for quality and durability, availability, safety and efficacy. Our teams also take into consideration medical and environmental requirements and other regulations.

**Strategic Quality Process (SQP)**
Boston Scientific manufacturing processes reinforce our quality policy and our overarching SQP, which is updated yearly and encompasses:

**Operations strategy:** How we establish our strategic goals and plans.

**Management systems:** How we prioritize and execute our work.

**Continuous improvement:** How we improve our work.

**Cascading metrics:** How we measure and connect performance.

**Recognition and engagement:** How we recognize teams and individuals.

To ensure cohesive quality throughout the enterprise, every one of our manufacturing sites uses the overarching SQP to develop its own SQP to support the facility’s focus and performance objectives.
Our Quality Policy is printed on employee badges and is highly visible in our facilities:

“I improve the quality of patient care and all things Boston Scientific.”

Our Quality Policy is complemented by our Quality Mission:

“We exceed expectations with customer-centric quality solutions that transform patient lives.”

GLOBAL QUALITY PROCESS: 8 PILLARS

1. Quality system management
2. Documents, records and data control
3. Design controls
4. Product approvals
5. Material controls
6. Production and process controls
7. Post-market support
8. Corrective action, preventive action
Measuring and Monitoring Quality and Compliance Effectiveness

We conduct regular audits to verify that our global quality system meets internal and external requirements and that it is implemented and maintained effectively. We follow up with activities that include re-auditing prior observations and confirming that the requisite actions were taken. Regulatory agencies also review our performance to ensure quality and compliance.

In 2020, to adapt amid the pandemic, our global quality team acted quickly to shift from in-person to virtual audit processes. We partnered with vendors to pilot new technologies for remote auditing and obtained legal and privacy approvals for camera and recording activity. This approach meant we were able to secure key regulatory approvals safely and on time.

Product Performance

Boston Scientific teams review customer and patient feedback and monitor experiences with our devices. This information is valuable for our quality system and for future product iterations and innovations. We follow a preventive action process to identify root causes for potential compliance and quality issues, and to develop preventive solutions. We initiate field actions as needed to ensure that any regulatory or field safety issues are resolved quickly and effectively.

"Customer insights are a key resource as we work to improve our products and introduce new devices. That’s how new generations of products are born.”

Alejandra Hernandez, senior engineer, Quality Systems
Pre-Clinical Sciences
We conduct extensive research into the safety and efficacy of our devices before progressing to human clinical trials. This pre-clinical research sets stringent standards that govern our training practices, product testing and regulatory compliance. In 2020, we made significant investments in our Research and Technology Center in Minnesota, including the latest in advanced imaging technology to help ensure device compatibility — an investment that will enhance R&D initiatives across all our businesses.

Clinical Trials
Our clinical trials are scientifically rigorous and generate the data we need to document that Boston Scientific products are safe and effective. We disclose the outcome of all primary and pre-specified secondary endpoints in trials we sponsor, regardless of whether the results are positive, negative or inconclusive. Our clinical teams adhere to criteria established by the International Committee of Medical Journal Editors for authorship on clinical trial publications. In publications pertaining to research that has been supported by Boston Scientific, our teams disclose the company’s involvement, whether as a sponsor or supporter.

In 2020, we strengthened and refined our operating procedures to ensure we meet or exceed EU MDR requirements by the required deadlines.
Building Digital Capability

Our recent investments in digital platforms gave us capabilities that were critical for providing remote customer support in 2020. Highlights include:

- Aided practitioners remotely using our augmented reality platform to offer expert guidance on product use and assist with setup and troubleshooting for devices and procedures.

- Partnered with a wearable technology company to pilot a smart glasses device that enables 225 customers in Latin America to receive real-time remote guidance from Boston Scientific clinical specialists — assistance that helped nearly 1,200 patients.

- Developed and launched provider tools and resources for re-engaging with patients in the wake of the pandemic.

- Offered on-demand webinars and telehealth resources for providers on COVID-19-related legislation, regulations and protocols.

- Used our Heart Connect™ system to conduct over 13,000 remote follow-up device checks with customers.

The company’s digital capabilities also allowed many employees to work remotely during the pandemic. We established new operating procedures and launched online tools so our employees could collaborate virtually with colleagues inside and outside the company.

We are working closely with the FDA on their new Digital Health Software Precertification Pilot Program. The goal of the program is to offer precertified companies a streamlined premarket review that will ultimately result in faster patient access to safe and effective software-based medical innovations.
In October, Boston Scientific hosted our annual Recognize Success event, where we celebrated cross-functional teams that are making outstanding contributions to improve quality, patient care and operational effectiveness.

Innovation in a Virtual World
Throughout 2020, we remained steadfast in our commitment to transform lives. Using virtual platforms, we continued internal innovation initiatives such as:

- **Recognize Success**, a program that celebrates contributions by teams that have innovated to improve quality, efficiency and agility at Boston Scientific.

- **Recognize Development Excellence**, an initiative that honors cross-functional teams that develop meaningful innovations for customers, patients and our company.

- **ImagineIF**, an internal venture capital-style approach to funding breakthrough employee ideas which could have a positive impact on any aspect of our company.

In addition, Boston Scientific launched the COVIDea portal in March to collect employee ideas on how to help slow the spread of the coronavirus and support relief efforts. We received more than 100 submissions and pursued several proposals to develop and donate personal protective equipment and medical equipment, many of which are featured in this report.

SUPPORTING DIGITAL INNOVATION: THE CONNECTED PATIENT CHALLENGE

Digital health solutions that improve patient and caregiver quality of life at home was the theme of the fifth annual Boston Scientific Connected Patient Challenge. The external competition, co-sponsored by Massachusetts Life Sciences Center and others, promotes the development of digital innovation to address complex health care challenges. In early 2020, six finalists participated in a live pitch event with life science professionals and industry experts. The winning submission was the VaGenie, a connected pelvic floor muscle training device that can help prevent issues related to having a weak pelvic floor, including incontinence and lower back pain.
Collaborating with Customers

Boston Scientific is deeply committed to helping health care providers meet patient needs. We gather customer feedback in several ways to inspire future product iterations and develop solutions collaboratively. For example, our anatomical model lab in Minnesota enables engineers and physicians to evaluate new product concepts on-site or remotely using new collaboration and visualization tools.

Through the Motion Medical joint innovation accelerator with the Mayo Clinic, we made progress developing minimally invasive treatments for conditions that impede quality and longevity of life. In 2020, we refined two prototype devices, one for patients with cancer and another for patients with structural heart disease. In 2021, these projects are proceeding to final verification, validation and preclinical testing.

INNOVATING WITH URGENCY DURING THE PANDEMIC

To support demand for ventilators and personal protective equipment (PPE), we teamed up with customers and health care industry peers to develop and distribute innovative solutions to address critical medical needs in our communities.

Ventilator Alternatives. We collaborated with the University of Minnesota Bakken Medical Device Center and industry partners to bring the Coventor resuscitator to market, with less than 60 days from concept meeting to production completion. The machine pumps a resuscitation bag at regular intervals, replacing the need for manual respiration in emergency settings. After receiving FDA Emergency Use Authorization in April 2020, our partnership delivered nearly 3,000 Coventor resuscitators to health care providers.

PPE. Working with Stanford University and an international coalition of medical experts, clinicians and industry leaders, we developed the Pneumask™ Face Shield in 38 days and received FDA Emergency Use Authorization shortly thereafter. The device combines a full-face mask and a Boston Scientific custom-molded adapter that attaches to a medical-grade air filter. We donated over 1,500 Pneumask Face Shields to hospitals across the United States and have given other manufacturers access to design details for future production.

Nearly 3,000 Coventor resuscitators were delivered to health care providers
Boston Scientific collaborates with a variety of academic institutions, research organizations and accelerators around the globe to promote innovations in health care, including:

- **gBETA Medtech**, a free Minnesota-based accelerator that helps early-stage health care startups.
- **MEDX Xelerator**, a medical device and digital health incubator, based in Israel, that’s focused on innovations across multiple disease states.
- **PracticePoint**, a membership-based health care R&D facility operating at Worcester Polytechnic Institute in Massachusetts.
- **BioInnovate**, a program at the National University of Ireland Galway that fosters medical device innovation using a needs based approach from Stanford University Biodesign.
- **Avicenna Alliance**, an industry and academic collaboration to promote an EU framework embracing in-silico methods, computer modeling and simulation.
- **HuaXi-Boston Scientific Joint Innovation Center**, a collaboration with Huaxi Hospital in Chengdu, China launched in September 2020 to bring innovative solutions to patients via remote education.
- **Medical Device Innovation Consortium**, a public-private partnership with the FDA to advance solutions that promote patient access to innovative medical technologies.

Boston Scientific R&D employees testing new components for the ROTAPRO™ Rotational Atherectomy System in the anatomical model lab.
Global Customer Care

In 2020, our global customer care team expanded its framework and capabilities to improve customer support. These enhancements enabled us to shift more resources to manage customer relationships, anticipate product needs and advise on solutions.

- We introduced Salesforce.com Service Cloud in 16 countries to better serve customers and increase online collaboration.

- In the EU, we invested in technology to increase automated ordering to more than 80 percent of volume, allowing employees to spend less time handling orders and more time talking with customers about their needs.

- Using robotic process automation shipping, we reduced cycle time for sales and sales support agents and improved field inventory levels.

"Technology solutions represent a huge opportunity for our customers to provide better care to patients. Our teams are focused on what's going to help providers and patients the most."

Hans Willems, vice president, Global Customer Care and EMEA Supply Chain

More than 750 dedicated Customer Care team members across 40 unique sites
Value-Based Health Care
A global Boston Scientific team is dedicated to studying health economics to demonstrate the value of our technologies and increase market access for providers and patients through policy and reimbursement advocacy.

Chronic conditions among an aging population present challenges to health care access and affordability. A study in the Journal of the American Heart Association showed significant cost savings when patients who are at risk for stroke due to atrial fibrillation undergo a one-time, minimally invasive procedure to implant the WATCHMAN™ Left Atrial Appendage Closure Device rather than receive lifelong anticoagulant treatment.

We use a combination of science and technology to help identify patients who are likely to become sick or experience a sudden health event, giving providers more opportunities to take preventive action and keep patients healthier at more affordable costs.

The Boston Scientific HeartLogic™ Heart Failure Diagnostic technology is embedded within implantable defibrillators and uses multiple sensors to collect and analyze patient physiological data. The technology has been proven to predict heart failure events an average of 34 days before they happen, which enables proactive care and helps reduce patient hospitalizations and readmissions.
Investing in Our People

At Boston Scientific, we are fortunate to have approximately 38,000 employees around the world whose constant focus is developing solutions that change and save lives.

Their talent and collective passion define us as a company, and our performance as a business is built on their diversity of thought and experiences. Our business practices reflect our belief that innovation thrives when employees are highly engaged in their jobs and communities, and with one another. We invest in our people so they can solve problems and advance promising ideas, and we recognize and reward them for their contributions.
In 2020, Stephanie Pittman, who has been with Boston Scientific for 10 years, took on the role of vice president of Global Talent Management and HR Planning in 2020.

“Our global workforce expects meaningful work with career advancement opportunities. We are enhancing our workforce planning strategy and development capabilities to meet those needs both now and in the future. This includes expanding virtual learning offerings, investing in digitally enabled analytics and increasing the ways we listen to gain insight and take action.”

Stephanie Pittman, vice president, Global Talent Management and HR Planning

SUSTAINABLE DEVELOPMENT GOALS:

Meaningful Innovation
High Performance
Global Collaboration
Winning Spirit
Caring
Meaningful Innovation
Diversity
Our Core Values
Global Strategic Talent Management and Planning

Our efforts to recruit, promote and retain diverse talent are focused on cultivating inclusive behaviors and building an organization that prioritizes continuous learning and the following:

**Talent management and planning:** apply analytics and insights to hire and develop diverse, high-potential talent and facilitate their movement to new roles.

**Manager development:** improve managers’ performance and career coaching capabilities, inclusive leadership behaviors and agility in adapting to change.

**Culture and engagement:** measure the employee experience through data and ongoing dialogue and act on the results.

**Employee growth and development:** provide development opportunities for all employees, as well as tailored programs for top leaders and key talent; this includes accelerating meaningful advancement opportunities for women and multicultural talent.

Our progress in talent management included the transition to what we have named, “Performance Development Coaching (PDC) 2.0,” an ongoing people development approach. Slated for companywide adoption in 2021, PDC 2.0 enables employees to receive continuous coaching and to request performance feedback from supervisors and colleagues as projects are completed and evaluated.

**PIVOTING TO PDC 2.0**

**FROM:**
- Formal review meetings twice a year
- Comprehensive feedback limited to scheduled reviews
- Companywide timing
- Structured review events

**TO:**
- Ongoing feedback as needed
- Brief feedback and coaching conversations relevant to current work
- Supervisor or direct report initiates discussions as needed
- Feedback and coaching intervals integrated into regular work meetings, reinforcing ongoing development conversations
Employee Growth and Development

Boston Scientific provides tools and training for continuous learning so every employee can envision greater possibilities for their career.

- We offer more than 150 professional and technical courses, including on-the-job training, skills-based education and programs for employees who have the potential to hold leadership positions.

- Responding to the realities of the pandemic, the company ramped up virtual training and development. People at all levels of the company now have access to more than 100 new and expanded webinars, online courses and on-demand training.

564K hours spent by non-manufacturing employees in 2020 virtual and classroom training

150+ professional and technical courses offered

100+ new and expanded webinars, online courses and on-demand training
Fostering a Diverse, Equitable and Inclusive Culture

To promote equity and cultivate an enduring culture of inclusion, we must hold ourselves accountable as an organization. We have made steady progress, and at the beginning of 2020, we set our diversity, equity and inclusion goals even higher with three new bold measures to accelerate the representation of women and multicultural talent in our workforce. Based on our belief that the only acceptable trajectory for diverse representation is up, we call these goals “3Up by 2023.”

3UP BY 2023

- Increase our goal of representation of women at the supervisory and managerial level to at least 43 percent — an increase of 3 percentage points
- Increase our goal of representation of multicultural talent at the supervisory and managerial level to at least 23 percent — an increase of 3 percentage points
- Top 10%: Continue to be in the top 10 percent globally as a recognized leader for workplace inclusion

DE&I EFFORTS ACROSS BOSTON SCIENTIFIC ALIGN WITH FOUR STRATEGIC PILLARS

Greater representation and inclusivity is about progress over time, not overnight. Learn more about why DE&I is a business imperative for Boston Scientific.
In 2020, four Boston Scientific employees were selected to participate in the CEO Action for Racial Equity, a fellowship that provides representatives of CEO Action for Diversity & Inclusion signatories an opportunity to advance racial equity through public policy. The fellowship is governed by the CEO Action for Racial Equity Governing Committee, a group of 20 CEOs who represent multiple industries and regions, including Boston Scientific Chairman and CEO Mike Mahoney, a founding signatory of CEO Action.

“This fellowship aligns with my own values and enables me to take responsibility — as a white woman of privilege — in the journey to advance racial equity.”

Caroline Jacobsen, manager, Health Economics
Advancing Multicultural Talent
To address the need for more Black, Hispanic and Latinx employees at the manager and supervisor levels, we expanded our diverse hiring and training programs and increased our investment in ally and mentorship initiatives. We also designed new programs specifically for Black, Hispanic and Latinx employees who build our medical devices to prepare them for business roles. These programs are expected to launch in 2021.

Inclusion Resources
The DE&I dashboard we developed in 2019 proved to be a valuable analytics tool in 2020 as we took stock of where we can address shortcomings and make measurable improvements. Our leaders use DE&I analytics to better understand representation trends in their organizations and identify ways to improve hiring, promotion and attrition metrics.

Over the course of the year, we expanded our virtual inclusion resources.
- Inclusion toolkit. The online toolkit encourages employees to take the I Act On Pledge and complete an assessment to determine their inclusion IQ. It offers on-demand DE&I tools as well as learning modules on topics such as unconscious bias training, modeling inclusive behaviors and anti-racism.

- Candid conversations. The Candid Conversations podcast is an interview series that builds on our inclusion training and Real Talk listening sessions. In 2020, we expanded opportunities for people at all levels of the organization to tell their stories and offer perspectives on handling issues such as parenting during the pandemic, racial injustice and mental health.

REAL TALK IN 2020
As racial inequity and injustice dominated the dialogue in and outside the company, we took steps to engage in necessary, sometimes uncomfortable, conversations to break the silence about race and identity. Leaders and our HR and DE&I teams led more than 200 hours of Real Talk listening sessions, engaging employees throughout the organization in dialogue on the root causes of racism. We covered topics such as what it’s like to be Black in corporate America, white privilege as well as disparities in the workplace and barriers to diversity.

Rob Morton (left), and his mentor Matt Lavelle, vice president, Operations (right) held one of the first Real Talk sessions.

“Things like race have a negative stigma associated with being talked about at work. If sharing our conversation influences just one person then it was a success.”
Rob Morton, senior scientific communications specialist, Medical Affairs

Employees engaged in 200+ hours of “Real Talk”
Employee Resource Groups (ERGs) are vital collaborators in our DE&I strategy. ERGs are voluntary, company-sponsored groups of employees who champion opportunity for all in our work environment and provide feedback to executive leaders through the company’s Global Council for Inclusion. ERGs are typically formed around specific dimensions of diversity, for example, gender, race, veteran status, sexual orientation or life stage. All employees are welcome and encouraged to join any ERG.

In 2020, Boston Scientific leaders and employees participated in our first global ERG summit. We examined the impact that the pandemic has had on our employees, particularly through the lens of diversity, equity and inclusion. More than 850 members of the company gathered virtually for panels and breakout sessions to share perspectives on inclusion and belonging.

GLOBAL ERG SUMMIT: INCLUSION AND BELONGING DURING THE COVID-19 PANDEMIC

In 2020, Boston Scientific leaders and employees participated in our first global ERG summit. We examined the impact that the pandemic has had on our employees, particularly through the lens of diversity, equity and inclusion. More than 850 members of the company gathered virtually for panels and breakout sessions to share perspectives on inclusion and belonging.

ERG PERSPECTIVE FROM BRIDGE: DEVELOPING A COMMUNITY OF BLACK LEADERS

Precious Morton joined Boston Scientific in 2007 and founded the Spencer, Indiana chapter of Bridge, our ERG focused on developing a community of Black leaders. She is now a quality manager in Alpharetta, Georgia and the global lead of Bridge. To recognize her contributions to DE&I, the Boston Scientific Global Council for Inclusion honored Precious with a 2020 Diversity, Equity and Inclusion Impact Award for her leadership and courage in bringing Black employees together to support one another and give voice to racism and injustice to drive meaningful change inside and outside the company.

“Everyone should be heard and accepted for who they are. People need a sense of belonging and purpose. I affectionately call my Bridge colleagues The Fam, because they are my family. The ERGs at Boston Scientific give us a safe space in a not-so-safe world. We learn from one another, and we make a positive impact on the company and on our communities.”

Precious Morton, quality manager, Pathology

6,000+ employees across nine ERGs
110 chapters globally
42 chapters outside the U.S.
11 virtual chapters
The COVID-19 pulse survey gauged whether employees felt supported during the pandemic and allowed us to quickly adapt companywide efforts as necessary. Distributed to a representative sampling of approximately 9,000 indirect labor* employees, and with an 80 percent participation rate, feedback showed that employees:

- **Trust**
  - senior leaders and believe they care about employee well-being.

- **Value**
  - frequent, transparent COVID-19 communications.

- **Feel**
  - they have access to helpful resources and information, although some had difficulty finding certain well-being resources.

- **Appreciate**
  - the flexibility in where and when they work, although some expressed workload concerns.

*Indirect labor includes employees who are not directly involved in the manufacturing of products.

### Listening to Our People
Our people have a prominent voice in how we conduct business and the actions we take as a global citizen. To support this work, we invested in an on-demand, pulse survey tool that allows us to gather feedback on timely topics that can quickly be turned into action.

### People Leadership Survey 2020: Employees Rate Managers on Leadership Behaviors

- More than 26,000 employees invited to give survey feedback on 4,800 people leaders.
- 77% employee response rate.
- 95% of participating managers* received a personalized feedback report.

*Those with one or more direct reports responding.
Benefits to Fit People’s Lives

Employee benefits at Boston Scientific reflect our belief that well-being, financial health and security are essential for a productive and collaborative workforce. We strive to offer benefits that are valued by our employees, promote well-being and support life-work integration. Our Global Benefits to Fit Your Life program provides employees with a broad range of offerings to support and improve their lives.

Compensation

At Boston Scientific, we pay for performance. Where it is relevant to an employee’s responsibilities and in compliance with applicable law, we offer both a base salary and variable compensation. Our variable pay components include annual bonus programs, long-term incentive stock awards, and one-time performance and recognition rewards for highly successful projects and breakthrough performance.

Equal Pay for Equal Work: Pay Equity

We pay people equally for equal work. Our compensation experts regularly benchmark salaries and conduct companywide and external parity audits. We contract with an independent third party to assess pay equity across all positions using regression analysis. This data-driven approach controls for variables that influence compensation such as job position, tenure, years of experience and location. We use the results to identify any potential pay disparities, and we address these accordingly. In our last assessment, conducted in 2019, we continued to see 99+ percent pay equity for gender globally and 99+ percent pay equity for multicultural talent in the United States, including Puerto Rico. Our compensation team will conduct another third-party global pay assessment in 2021.

Employer of Choice Awards

Boston Scientific is committed to be an employer of choice for globally diverse talent. We participate in external benchmarking surveys that candidly assess our progress and ensure we are doing all we can to achieve our goals. Visit our awards page to learn more about the recognition we received in 2020.
As employees adjusted to life and work during the pandemic, we moved quickly to help them and their families by shortening meeting times, holding managers accountable for supporting their teams with flexible hours, and regularly communicating available resources.

Through employee surveys and listening sessions with working parents and other caregivers, we continued to assess how best to support our workforce. As a result, we added new benefits and expanded other offerings:

- expanded no-cost, virtual offerings for general medicine and mental health support.
- doubled the time available under our Personal Leave of Absence policy, and made it available to use in half- or full-day increments.
- increased child and adult care-giving benefits, including adding more caregiver resources and offering home schooling support such as virtual tutoring, learning pods and return-to-school guides.
- modified our financial benefits for people facing economic hardship.
- launched an internal well-being website and well-being circles to provide employees opportunities to connect over shared interests and circumstances.

**COVID-19: BENEFITS EXPANSION AND UPDATES**

**A BOOST IN PANDEMIC BENEFITS**

- Covered COVID-19 testing.
- Doubled backup child care and elder care days.
- Upheld flex work hours and U.S. Flex Fridays.
- Revised policies to support workplace flexibility.
- Expanded personal leave.
- Enhanced global employee assistance programs.
- Expanded counseling benefit.
- Introduced well-being tools and resources, including podcasts, webinars and interaction opportunities.
- Launched virtual well-being circles.
- Expanded telehealth options.
- Expanded 24/7 emotional support.
Prioritizing Employee Health and Safety

Boston Scientific takes a global approach to prioritizing, delivering and monitoring employee safety at all our offices and facilities. We set health and safety goals called Total Recordable Incident Rate (TRIR) targets for every Boston Scientific operations site. Our global Employee Health and Safety (EHS) Operations Council reviews their performance monthly to discuss trends and risks, as well as opportunities for improvement.

In accordance with the Boston Scientific Environment, Health and Safety Policy, we integrate multiple health and safety metrics in our monitoring systems at the local and global levels. The policy is supported by our global EHS Essentials, which sets 143 specific expectations across 25 health- and safety-related programs.

Our Occupational Health Council provided valuable employee assistance during the pandemic. They established a centralized helpline, staffed by Boston Scientific physicians and occupational health nurses to help guide employees with COVID-19-related queries. We also offered voluntary COVID-19 testing to our on-site employees to help reassure them of the effectiveness of our protective processes.

We conducted a workplace survey of more than 25,000 employees to ask about their remote work experience during the pandemic and their preferences moving forward. Responses showed that working remotely has changed many employees’ thinking about their ability to work effectively from home and has made them more receptive to different types of office environments.

WORKPLACE STRATEGY: NOEL FINNERTY

“Noel Finnerty, director, Global Real Estate and Facilities

The dual challenges of climate change and a global pandemic have made designing safe, sustainable and efficient workplaces even more important for companies and their employees.”

TOTAL RECORDABLE INCIDENT RATE (TRIR)

<table>
<thead>
<tr>
<th>Year</th>
<th>TRIR</th>
<th>Goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>0.47</td>
<td>0.25 TRIR</td>
</tr>
<tr>
<td>(0.47 injuries per 100 employees)</td>
<td>(0.25 injuries per 100 employees)</td>
<td></td>
</tr>
</tbody>
</table>

In 2020, we navigated the ongoing challenges of the pandemic in the various countries where our employees live and work. Boston Scientific took immediate action to develop global COVID-19 guidance, restrictions and workplace protocols, including:

- Flexible work arrangements for employees who could work from home.
- Travel restrictions and protocols.
- Company and site safety protocols.
- Workstation reconfiguration.
- Limited sales visits to critical cases.
- Accelerated capabilities to provide remote physician support.
- Advanced cleaning protocols.
- COVID-19 employee resources website.
- Office space modifications and new building procedures.
- COVID-19 testing and personal protective equipment (PPE) for employees.
- COVID-19 contact tracing.
- Augmented platforms for remote practitioner case support.

4,655 employee calls to our physicians and nurses in 2020
5,482 COVID-19 tests for on-site employees in 2020
Advancing Possibilities

Our commitment to transforming lives inspires us to address inequities in the world around us.

Boston Scientific collaborates with local communities, nonprofit organizations and providers to understand and address disparities within underrepresented populations. Whether we are improving treatment disparities for Black, Hispanic and Latinx people, providing students access to STEM opportunities, or empowering employees to take action in their communities, we are advancing possibilities for societal good.
**Confronting Health Inequities**

For more than 15 years, Boston Scientific has worked to eliminate health care inequities in underserved communities through our industry-leading program Close the Gap. More recently, and as the pandemic exposed the severity of treatment disparities and systemic barriers to care, we stepped up our efforts to help providers identify and serve diverse populations.

Through Close the Gap, Boston Scientific launched a public awareness campaign focused on health inequities related to heart and vascular disease outcomes in the U.S.

In 2020, Paige Bingham became the national program director of Close the Gap. A longtime health equity champion, Paige offers insights on the team’s work to address treatment disparities and increase diversity in clinical trials.

“**The Boston Scientific Close the Gap program empowers physicians with data and epidemiological insights to identify local treatment gaps and customizable resources to reach vulnerable populations. This approach helps to inform and activate measurable change to save lives.**”

Paige Bingham, national program director, Close the Gap

In 2020, Boston Scientific launched a public awareness campaign focused on health inequity awareness.
Addressing the Gaps: COVID-19 Heart Study
The most vulnerable populations are at the greatest risk for conditions such as heart disease, but they are the least studied in large-scale clinical trials. According to census data, Black Americans represent 13.4 percent of the U.S. population, yet peer-reviewed research shows they make up only 5 to 7 percent of clinical trial participants.1 In 2020, we began work with Yale/Yale-New Haven Hospital Center for Outcomes Research and Evaluation (Yale-CORE) to increase the diversity of representation in the Boston Scientific COVID-19 Heart Study, developed to better understand how COVID-19 affects people with heart conditions.

IN THE UNITED STATES:

13.4% of the population is Black

Only 5–7% of clinical trial participants are Black


Paul Underwood, MD, and medical director at Boston Scientific, has been working to reduce health disparities for women and people of color since 1990. He made it his mission to fight racism.

“The data show that the most vulnerable populations have the greatest risk of heart disease but are the least studied in large-scale clinical trials. The opportunities to make an impact are fantastic when we use objective data to guide the way. I am so proud to be working for a company taking tangible actions to battle systemic racism.”

Paul Underwood, MD, medical director, Boston Scientific
Playing Our Part: Combating Racism

Racism in the United States and around the world was front and center in 2020 as we witnessed the tragic death of George Floyd, preceded by those of Breonna Taylor, Ahmaud Arbery and so many others. The Boston Scientific Executive Committee issued an open letter reaffirming the company’s commitment to contribute to a more equitable and inclusive society where all people feel safe and valued and have a voice. As part of that pledge, Boston Scientific is donating $3.5 million over a multiyear period to combat inequity, systemic racism and injustice in our communities. We are also accelerating our internal diversity, equity and inclusion programs, which include initiatives that address discrimination and racism.

$3.5 million to combat racism and advance social justice

**Community**  
Expand the conversation on anti-racism and support social justice organizations

**Economic Empowerment**  
Accelerate the development of Black-owned businesses

**Education**  
Educate and create professional opportunities for Black youth

**Health Care Disparities**  
Address health care disparities in the community

**Government/Policies**  
Advocate for change

COMBATING RACISM STRATEGY
Supporting Our Communities

The work we do is about caring for human life, and it draws us into the communities where we live and work. Our employees help us shape the way we care for the world around us. In 2020, employee engagement expanded to 54 countries and philanthropic contributions focused on the coronavirus pandemic, social justice and natural disasters.

Our global community engagement is focused on three key areas:

**BSC CONTRIBUTIONS AND ENGAGEMENT**

54 countries
Employee community engagement

$70 million
Contributions for medical research, fellowships, educational and charitable giving

$1.2 million
Boston Scientific Foundation contributions

+1,700 nonprofits supported with donations or grant funding

**Advancing education**
To develop diverse talent who will create health solutions for generations to come, we support science, technology, engineering and math (STEM) programming for underserved 5- to 18-year-old students around the world.

**Advancing health**
To decrease health disparities in chronic diseases among underserved communities, we aim to provide access to quality care, support disease prevention and help prepare children for a healthy journey into adulthood.

**Advancing community**
To improve life in their local communities, we empower our employees to donate their talent and resources through our strategic matching gifts and volunteer programs.
In August 2020, an explosion in Beirut killed more than 200 people, injured more than 7,500 and left an estimated 300,000 people homeless. Boston Scientific Peripheral Interventions Training Manager Rawad Abou Dihn, who has a nursing background, quickly rallied colleagues and friends to turn the entrance of a local building into an emergency wound clinic. The team provided critical aid to an average of 100 people daily and helped reduce the tremendous strain on hospitals overwhelmed with critically wounded people and COVID-19 patients.

**RELIEF EFFORTS**

When an event occurs that devastates one of our communities, Boston Scientific works to ensure employee safety, assess impact and determine how the company can support relief efforts. For example, in 2020, the company coordinated and encouraged employee donations to help people affected by the wildfires in Australia and California, Hurricane Laura, the explosion in Beirut, the coronavirus epidemic as well as victims of social injustice and racial inequity. Employees who chose to donate to these efforts received a matching financial contribution from Boston Scientific.

**TAREK EL RAHBANI**

Tarek El Rahbani led local efforts to support Boston Scientific employees and operations in Beirut following the explosion.

“As a Lebanese Boston Scientific employee, I am grateful for the support we received from colleagues around the world and proud of the quick actions taken by Rawad and volunteers. Our commitment to our caring core value is evidenced by how our employees responded with compassion and integrity.”

Tarek El Rahbani, managing director, Middle East, North Africa, Turkey and Central Asia

**35% annual increase of employees participating in global matching gifts program**
In Marlborough, Massachusetts, employees made and donated masks and other items to local nursing homes, hospitals and homeless shelters.

In Galway, Ireland, employees lifted spirits by donating critical supplies, including gloves, masks, coveralls and boxes of chocolate Easter eggs, to local nursing homes.

In Singapore, employees packed and donated more than 350 kits filled with essential items such as hand sanitizer, face shields and healthy snacks to local nursing home residents and health care workers.
In an urgent 2020 undertaking called Project Shield, Boston Scientific employees assembled and donated one million face shields in just over one month. Urology Research and Development (R&D) Project Manager Alissa Brandon came up with the idea and collaborated with colleagues to launch the initiative. The effort rapidly expanded to include:

- 12 Boston Scientific sites.
- More than 400 employees around the world contributing their time and expertise.
- They also collaborated with the grassroots organization GetUsPPE, to deliver the PPE to health care facilities in more than 40 U.S. states and territories.

“This shows what can be accomplished when a team with a lot of heart and know-how comes together to collaborate. So many people stepped up to contribute and help scale this project to where it is today. I am grateful for our caring team who demonstrated heroic hustle.”

Alissa Brandon, R&D manager, Urology
Global Signature Health Grant Program
The World Health Organization is estimating a shortage of 19 million health care workers in low- and lower-middle income countries by 2030. Recognizing this crisis early on, Boston Scientific launched a Global Signature Health Grant Program in 2016. Since then, we have partnered with nonprofit organizations that are working globally to increase the number of trained health care workers and improve the quality and availability of chronic disease screenings.

Global Signature Health Grant Collaborations Since 2016

**MEXICO:** Boston Scientific supported Partners in Health between 2017 and 2019 and trained newly graduated Mexican physicians in the diagnosis and treatment of chronic disease.

**COLOMBIA:** New in 2020, we support Project HOPE in its work with the Ministry of Health and local universities to deliver chronic disease training for providers caring for millions of Venezuelan refugees.

**SOUTH AFRICA:** Our grant to Project HOPE funded work that trained health care workers and created screening protocols for diabetes and hypertension from 2016 to 2018.

**INDIA:** Beginning in 2016, we collaboratively developed training tools with Project HOPE that support the diagnosis and treatment of chronic disease. New in 2020, our grant to Population Services International funds the creation of digital tools that better identify and follow patients living with chronic disease.

**MALAYSIA:** Since 2018, we have supported Children’s HeartLink to help create a regional center of excellence for the diagnosis and treatment of congenital heart disease in children.

The World Health Organization is estimating a **shortage of 19 million** health care workers in low- and lower-middle income countries by 2030.

“We are incredibly thankful for Boston Scientific’s commitment to improving the world’s health and for a partnership that is helping people around the world access the care they need.”

Rabih Torbay, president and CEO, Project HOPE

---

*Project HOPE, Population Services International*
Project HOPE Aid in Colombia

When Colombia declared COVID-19 a health emergency, Project HOPE redirected its efforts, and a portion of grant funding, to work with the Ministry of Health, Departmental Health Institute and local hospitals to train health care workers and non-medical staff, conduct COVID-19 screenings and distribute PPE.

- **5,616 people** screened for COVID-19.
- **94 health care workers** trained.
- **238 non-medical staff and local volunteers** trained in hygiene promotion, infection protection and control, and contact tracing.
- **7,543 health consultations** provided.
- **415+ full sets of PPE** distributed.
- **1,500 gloves** provided.
- **500+ protective lenses** distributed.
STEM Education
On-site events and in-person mentoring were put on hold for much of the year, but Boston Scientific found innovative ways to continue to bring STEM education to underrepresented youth. Around the world, STEM volunteers used new technology to expose students to careers in industries like ours.

- **China:** In honor of Children’s Day, our STEM team created “Know Your Body” videos, including How does air pollution harm your lungs? and Why lip color turns darker when your heart does not feel well.

- **Puerto Rico:** Employee volunteers gave elementary school students a virtual tour of our Dorado plant that featured an interactive pH experiment. High school students also had the opportunity to interact with an online panel of STEM experts and watch a video simulating a product being implanted.

- **Ireland:** To recognize Engineering Day, the team held a contest in which 8- to 12-year-old students had the chance to win a “STEM Day in a Box” that featured content and experiments in chemistry, engineering, physics and battery technology. More than 750 youngsters representing 46 schools in 25 towns participated in the contest.

34,000 kits packed that provided STEM activities, health and wellness essentials, and other necessities to populations in need around the world

Our Community Engagement team launched BSC Buddies, a program that connects employees’ school-aged children online across different geographies, cultures and languages. The 2020 pilot paired 400 children from more than 20 countries.
Protecting the Environment

Our commitment to improving patient health comes with a responsibility to protect the planet we all share.

As we work to solve health care’s toughest challenges, we are taking decisive action to reduce our environmental impacts and achieve carbon neutrality.
Responding to Climate Change

Boston Scientific sets ambitious climate change goals, and we are on track to meet our commitment to achieve carbon neutrality in all manufacturing and key distribution sites by 2030. We became the first medical device manufacturer to make such a pledge in 2017. Since the start of 2017, we have reduced our carbon footprint by 50 percent.

ACHIEVING CARBON NEUTRALITY:

Ronan Coffey has led our Global Energy Management System (GEMS) since 2018.

“Carbon neutrality is the right thing to do, and our C³ strategy is the right way to do it. Our Global Energy Management System has grown from being a new way to look at energy consumption to being the actual language we use to talk about energy management and carbon emissions. GEMS is built into how we work. Our teams are making great progress around the world.”

Ronan Coffey, global energy manager, Boston Scientific

SUSTAINABLE DEVELOPMENT GOALS:

C³ STRATEGY

A central component of the company’s carbon neutrality approach is our C³ energy strategy. Global and site teams collaborate across Boston Scientific to meet its objectives:

- **Cut**
  - energy use emissions.

- **Convert**
  - to renewable energy sources instead of depending on fossil fuels.

- **Compensate**
  - with carbon credits and offset projects for any remaining unavoidable emissions.
Boston Scientific is on track to achieving carbon neutrality in all manufacturing and key distribution sites by 2030.

Interim Goals:
- 50% renewable electricity by 2021
- 100% renewable electricity by 2024
- 90% renewable energy (all sources) by 2027

2020 HONORS
In 2020, Boston Scientific was named to the Dow Jones Sustainability Index (DJSI) for North America, a well-respected global benchmark for corporate responsibility. The list recognizes companies that deliver outstanding economic, social and environmental performance. Visit our online awards page to read more about our environmental honors and distinctions.
Using the GEMS approach developed in conjunction with the National University of Ireland, Galway, Boston Scientific is making measurable strides toward carbon neutrality. We track progress and report it publicly using five GEMS key performance indicators (KPIs).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carbon Footprint</strong>&lt;br&gt;(MT CO2eq)</td>
<td>Total amount of Scope 1 and Scope 2 greenhouse gas emissions emitted into the atmosphere from manufacturing and distribution sites. Measured in tonnes of carbon equivalent.</td>
<td>118,327</td>
<td>108,694</td>
<td>94,946</td>
<td>85,127</td>
<td>84,778</td>
</tr>
<tr>
<td><strong>Energy Use</strong>&lt;br&gt;(MWh)</td>
<td>Total energy Boston Scientific consumes annually to manufacture our products.</td>
<td>370k</td>
<td>367k</td>
<td>364k</td>
<td>355k</td>
<td>368k</td>
</tr>
<tr>
<td><strong>EM³</strong></td>
<td>An energy management maturity model to establish where in the 'energy journey' each manufacturing site resides on a scale of 0 to 5: (Minimal/Emerging/Developing/Advancing/Leading)</td>
<td>2.7</td>
<td>3.2</td>
<td>3.6</td>
<td>3.7</td>
<td>3.9</td>
</tr>
<tr>
<td><strong>Green Real Estate</strong>&lt;br&gt;(% of total)</td>
<td>Percentage of Boston Scientific real estate that is independently certified for energy efficiency by industry-leading bodies such as LEED for design and Energy Star or ISO 50001 for building operations.</td>
<td>27%</td>
<td>28%</td>
<td>32%</td>
<td>32%*</td>
<td>41%*</td>
</tr>
<tr>
<td><strong>Renewable Energy</strong>&lt;br&gt;(% of total)</td>
<td>Percentage of total energy consumed, generated from renewable sources, with BSC owning the renewable attributes.</td>
<td>Electricity Percent</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>5%</td>
</tr>
<tr>
<td></td>
<td>All Sources Percent</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>3%</td>
<td>6%</td>
</tr>
</tbody>
</table>
**Our Environmental Impact**

In 2020, we made significant progress in our C³ energy strategy to achieve carbon neutrality across our manufacturing and key distribution sites. By addressing the company’s energy consumption, carbon emissions and environmental designs, we are reducing our climate impacts.

### 2020 ENVIRONMENTAL ADVANCES

- **67% reduction** in greenhouse gas emissions since 2009
- **71% of purchased electricity from renewable sources**
- **94% of solid waste diverted from landfills**

---

**Working with sustainability-minded customers, since 2017, we increased the number of patients reached by 20% while reducing our carbon footprint by 50%**
Cutting Our Carbon Footprint

Tackling energy use is the first tier of our C³ approach. To improve energy use in our existing sites and develop new construction in an environmentally responsible manner, we adhere to internationally recognized programs such as Leadership in Energy and Environmental Design (LEED) or the ISO 50001 energy management system. In 2020, Boston Scientific green real estate increased to 42%, up from 27% in 2015, representing more than 3.8 million square feet of total company real estate. At a minimum, all newly constructed Boston Scientific buildings are LEED certified.

Our Green Real Estate Expands

- Energy Management System ISO 50001: 5 manufacturing sites, 1 distribution center
- Leadership in Energy and Environmental Design (LEED): 15 buildings

42% of Boston Scientific real estate is green — representing 3.8+ million square feet
Converting to Renewable Energy

Investing in and converting to renewable energy sources is the second action area of the C³ strategy. We monitor the percentage of the company’s energy generated from renewable sources, whether the energy is generated on-site or purchased from outside suppliers. In 2020, we stayed on track to meet our objective of sourcing or generating 100 percent of our electricity from renewable sources by 2024. We expect that by 2027, 90 percent of all energy at Boston Scientific facilities, including electricity and natural gas, will be renewable.

- Our Clonmel, Cork and Galway, Ireland facilities and our Kerkrade, the Netherlands distribution center source 100 percent renewable energy.

- Using hydroelectric, wind and solar power, our manufacturing sites in Heredia and Coyol, Costa Rica have been carbon-neutral since 2016.

- In our Marlborough and Quincy, Massachusetts locations, we have on-site solar installations that generated a total of 3.2 million kilowatt-hours of renewable electricity in 2020. An on-site solar installation at our Dorado, Puerto Rico facility, slated for completion in mid-2021, will deliver approximately 17 percent of the site’s electricity needs.

Compensating With Carbon Offsets

Carbon offsetting is the final step we consider taking to reach carbon neutrality. While our primary focus is on cutting energy use and converting to clean energy sources, we compensate with carbon offset projects when we have unavoidable carbon emissions or cannot yet rely on renewable energy options. Potential projects are carefully assessed to ensure the results will negate our remaining carbon emissions. For example, Boston Scientific collaborated with the eco-conscious platform Treedom in 2020 to plant more than 5,000 trees in Kenya. The initiative will benefit local communities and contribute to cleaner air in the region.

Climate Risk Management

Boston Scientific has begun integrating climate-related financial disclosures into the way we manage climate-related risks and opportunities. In 2021, we will complete a comprehensive assessment of our business risks associated with climate change.

By 2027, we expect 90% of all energy used in Boston Scientific facilities will be renewable.
**Conserving Water**
Water is a critical shared resource, and we are committed to managing its use responsibly. While Boston Scientific operations are not water intensive, we work to minimize consumption and prepare for water supply challenges. Based on an assessment using the World Resources Institute Aqueduct risk-mapping tool, we have determined that 11 company locations are at low overall water-related risk, and six facilities are in the low-to-medium risk category. Our efforts to assess water-related risks and opportunities will expand in 2021 to include the company’s significant commercial operations. Water usage at Boston Scientific manufacturing and major distribution centers is predominantly associated with employees, which accounts for 69 percent of our total water consumption.

**Waste Management and Recycling**
We are working to divert all non-hazardous waste from landfills and incineration by 2030. Boston Scientific facilities will participate in the TRUE (Total Resource Use and Efficiency) certification program to meet this objective. TRUE strives to change the way materials flow through society so that all products are eventually reused and diverted from landfills, incineration and the environment.
Results from Cork: Taking Recycling to the Next Level
After achieving a recycling rate of more than 90 percent, our Cork, Ireland team extended their success by recovering reusable materials. In 2020, they began setting aside plastic packaging made from Polyethylene Terephthalate, a material that can be ground into flakes and reused if properly isolated in the collection process. This approach also results in less processing energy than recycling. By taking this extra step, the team diverted 20 metric tons of plastic for recovery.

Success in Cork:
- **90%** recycling rate achieved
- **20 metric tons** of plastic recovered

Our Cork site made significant progress toward waste avoidance in 2020 — their recycling initiatives resulted in 20 metric tons of plastic recovered.

GLOBAL WASTE MANAGEMENT PERSPECTIVE: SEAMUS GETHINS

“Focusing on avoidance and reuse is key to reducing our environmental impact. For the future of our planet, we have a duty to go beyond standard recycling.”

Seamus Gethins, global director, Global Environment, Health and Safety
Boston Scientific is committed to conducting business with unwavering ethics, strong corporate governance and regulatory compliance.

We insist on integrity in all our working relationships inside and outside the company. Our practices protect human rights, promote accountability and ensure that we act responsibly as a global citizen.
Jessica Pill leads our efforts to ensure compliance with regulatory requirements while acting with integrity and living our core values.

“Despite how we’ve had to change the way we work this year, we are doing our part to keep each other safe and live our values while continuing to serve patients and navigate challenges together.”

Jessica Pill, chief compliance officer and vice president, Compliance

The Boston Scientific global compliance team provides employees with the resources and training they need to do business with integrity, treat customers and suppliers fairly, and report ethics concerns when they arise. Led by our chief compliance officer, the team collaborates across the company to monitor our activities and performance. The chief compliance officer reports quarterly to the risk committee of our board of directors and more frequently as needed.

The Boston Scientific global compliance team provides employees with the resources and training they need to do business with integrity, treat customers and suppliers fairly, and report ethics concerns when they arise. Led by our chief compliance officer, the team collaborates across the company to monitor our activities and performance. The chief compliance officer reports quarterly to the risk committee of our board of directors and more frequently as needed.

Compliance, Ethics and Integrity

Our work contributes value to the lives of patients, employees and people in communities around the world. Social responsibility is built into how we deliver innovations, collaborate and operate. Our employees have a shared commitment to:

- Act honestly and ethically in all company matters.
- Protect the privacy of patients, customers and employees.
- Treat one another with respect and fairness.
- Hold one another accountable to ensure quality in everything we do.

The Code of Conduct

Every employee is required to read and understand the Boston Scientific Code of Conduct, which is the foundation for all our business practices and relationships. Employees complete annual training on the Code of Conduct, as well as multiple mandatory training courses throughout the year that reinforce company policies, explain corruption- and compliance-related risks and provide resources for reporting concerns. Many of these trainings offer scenario-based content that help people respond ethically to issues they may face in their daily work.

We continually assess opportunities to adapt our Code of Conduct in light of developments in the global marketplace, including emerging technologies and business practices. In January 2020, we released an updated Code of Conduct with greater specificity about privacy rights, new language about maintaining a safe and healthy work environment, additional details about data privacy and expanded guidance on conflicts of interest.
Non-Retaliation Policy
The Boston Scientific Non-Retaliation Policy is an essential component of our compliance program. It prohibits any form of retaliation, direct or indirect, against an individual who raises a concern in good faith. This protection extends to anyone who assists with, or cooperates in, an investigation or report of misconduct.

Advice Line
All employees are responsible for immediately reporting any suspected violation of the Code of Conduct and related company policies. Ethics concerns may be confidentially reported through the Boston Scientific Advice Line. The toll-free, 24-hour service is operated by a third party seven days a week in multiple languages.

Global Human Rights and Labor Standards
We adhere to human rights and labor laws in every location where our company operates. In 2020, we finalized the Boston Scientific Human Rights Policy, which articulates our commitment to promoting human rights principles as recognized and understood by the international community. These principles include vigilance against modern slavery, human trafficking, bribery, discrimination and harassment.

Our human rights policy supports and is guided by the principles of the United Nations (UN) International Bill of Rights as well as:

- The Universal Declaration of Human Rights.
- The UN Guiding Principles on Business and Human Rights.
- The International Covenant on Economic, Social and Cultural Rights.
- The International Labor Organization Declaration on Fundamental Principles and Rights at Work.
- Global Reporting Initiative Sustainability Reporting Standards.

We also adhere to disclosure requirements under the California Transparency in Supply Chains Act and the U.K. Modern Slavery Act.
Risk Management and Global Security

Under the oversight of our board of directors, our enterprise risk management team supports company leadership with guidance to achieve performance objectives. The team analyzes strategic, operational, financial, legal and compliance risks to ensure we can adapt to challenges, pursue opportunities to help patients and meet commitments to stockholders. Led by our vice president of global internal audit, our risk management experts identify enterprise-level developments that could be barriers to meeting customer and patient needs or preserving and growing stockholder value. Any issue that presents a potential risk to the company’s financial results, operations or reputation is reported by management to the Board of Directors or one of its committees.

BEST-IN-CLASS GLOBAL SECURITY

The Boston Scientific global security and resiliency team was ranked in the top 10 of all U.S. manufacturers’ security departments in Security magazine’s 2020 Security 500 rankings. The team’s leadership has also been recognized for its commitment to diversity, equity and inclusion.

RISK MANAGEMENT: PREPARING TO HANDLE ANY SITUATION

Matt Sprague leads our team of risk management experts that identify enterprise-level developments that could be barriers to meeting customer and patient needs.

“The COVID-19 pandemic has broadened our definition of risk and expanded the scenarios we plan for in our risk management approach and processes, resulting in sharper action plans, escalation paths and lines of communication.”

Matt Sprague, vice president, Global Internal Audit
Business Resiliency
The Boston Scientific business resiliency strategy ensures that we can sustain operations and secure our facilities in the event of a crisis. Our global security and resiliency team plans and prepares for a range of potential threats, including wildfires, tornados, earthquakes, hurricanes and the effects of climate change. They use risk and impact assessments to plan for disasters or events that could interfere with our ability to deliver products for patients or jeopardize the safety of our people, suppliers or communities. The team also works closely with our IT disaster recovery experts to identify technology vulnerabilities so we can make the right investments to keep company operations secure.

When COVID-19 cases first emerged, our security, resiliency and medical teams acted quickly to protect our people and business operations while taking steps to ensure that our devices and therapies would continue to reach patients. Our employees provided on-site support to customers in accordance with guidance from local health authorities, as well as hospital protocols. To prevent on-site outbreaks and ensure extra safety, employees who could perform their job functions from home worked remotely with flexible work arrangements. We also shipped personal protective equipment (PPE) to company locations for employees’ use, provided COVID-19 testing for employees and issued pandemic guidance for teams globally. Based on virus-tracking data, we implemented new safety protocols, adapted facilities for social distancing and rolled out plans for the tiered resumption of manufacturing operations in locations where case counts subsided.

Business Continuity: Resiliency and the Global Pandemic
Ty Harris leads the company’s business resiliency efforts to help ensure continuity in operations and safety for our employees.

“We have a strong global resiliency model to protect the enterprise in the event of a crisis. In early January, when our global intelligence team alerted us to the COVID-19 outbreak in Wuhan, we were able to act immediately to anticipate the extent of the threat and keep employees safe. With new protocols and work streams, we kept critical operations intact and created work environments without community-spread at our sites.”

Ty Harris, director, Global Security and Resiliency

Protecting Global Assets
Our global security and resiliency team ensures the safety of our people as well as enterprise assets and operations. The team uses industry-standard protocols and global situational awareness tactics to manage our security posture and to maintain a global security operations center 24 hours a day, seven days a week. Their work to maintain and enhance physical security and cybersecurity is supported by a network of partners specializing in cybersecurity, environment, health and safety, supply chain, global regulation and data privacy.
Governance

The Boston Scientific Board of Directors has well-established corporate governance guidelines and adopted written charters for each of its standing committees (audit, executive compensation and human resources, risk, nominating and governance). Our Code of Conduct reflects the company’s commitment to good corporate governance and compliance with the rules and listing standards of the New York Stock Exchange and other legal requirements.

Global Tax Strategy and Compliance

Our business makes a positive economic and social impact around the world, strengthening the communities where our people live and work. In keeping with our commitment to social responsibility, we prioritize our role as a responsible taxpayer. We comply with all applicable tax laws, regulations and related disclosure requirements in every jurisdiction where we operate. Our tax professionals are committed to the highest compliance standards and use processes based on standardization and automation to minimize our tax risk.

Political Involvement and Contributions

Boston Scientific supports public policies that promote diversity, equity and inclusion and improve patient health, our employees’ lives and the communities we serve. We advocate for policies that focus on increasing patient access to life-changing and life-saving technologies. The company posts annual updates on contributions to political action committees, corporate contributions to state officials and memberships in associations that engage in public policy advocacy.

To advance sound public policy, the Boston Scientific Corporation Political Action Committee (PAC) facilitates voluntary political contributions by eligible employees and our board of directors in accordance with federal law. While the PAC supports our company values, it does not accept any contributions made on behalf of any corporations, including Boston Scientific, nor does it contribute to presidential campaigns. The PAC is run by a governing board of senior employees who represent our primary businesses. The nominating and governance committee of our board of directors annually reviews political contributions made by our company and the PAC. Contributions to political candidates are bipartisan, and to be eligible for funding, candidates must meet one or more of the following criteria:

- **Policy alignment**: The candidate is aligned with the company’s top public policy priorities; or,

- **Leadership and jurisdiction**: The candidate serves in elected leadership within the Congress and/or sits on a congressional committee with jurisdiction over issues impacting our business; or,

- **Constituency**: The candidate represents a district or state in which a company facility exists and/or serves a significant population of our employees; or,

- **Values and reputation**: The candidate’s character and integrity align with BSC’s corporate reputation and values.
Setting Industry Standards
Boston Scientific collaborates with trade associations and regulatory bodies around the world to set new standards in quality and stay informed about regulatory developments so we can be agile in our response. We make it a priority to help shape industry and regulatory approaches to quality by sharing the best practices behind our patient-centric systems.

- FDA Digital Health: We are working closely with the FDA through the Digital Health Software Precertification Pilot Program to expedite patient access to safe and effective software-based medical innovations.
- Medical Device Innovation Consortium: We are part of this public-private partnership with the FDA to advance solutions that promote patient access to innovative medical technologies.

Responsible Marketing
Boston Scientific is committed to ethical and responsible marketing and promotion. Our Code of Conduct and other employee policies emphasize the importance of fair and honest communications with patients, customers and the public. The company’s sales and marketing training for all customer-facing employees covers fair and honest marketing practices, respect for intellectual property, interactions with physicians and public officials, and conflicts of interest.

2020 Responsible Sales and Marketing Training:

$1.9 million invested in sales and marketing training programs

+12,000 hours of training for customer-facing employees
Sustainable Supply Chain

The company’s manufacturing and supply chain teams lead our efforts to plan, source, manufacture and distribute more than 17,000 products to customers and patients worldwide. More than 22,000 indirect and direct suppliers meet the highest quality standards for materials and service, ethical conduct, and compliance with all applicable laws and regulations. To identify supply chain partners supporting product development and ongoing supply for manufacturing, we use a standardized supplier performance tool that assesses each organization’s business practices and corporate citizenship. This protocol enables us to build relationships with responsible, high-performing suppliers who make significant contributions to our work.

PROTECTING SUPPLY CHAIN STABILITY IN 2020

In early 2020, the Boston Scientific global sourcing team shifted resources to keep our supply chain stable; as a result, we did not experience manufacturing outages amid the pandemic. The interventions we took included:

- Tracking supplier status and inventory in risk areas and taking action to prevent shortages.
- Monitoring safety stock levels and building up product supplies as warranted.
- Mitigating risk for technology and material shortages by identifying new vendors.
- Analyzing continuity risks by product family.

Supporting Supplier Diversity

Our approach to supplier selection involves building diversity, equity and inclusion throughout the Boston Scientific supplier network. In 2020, as part of our combating racism strategy, we took steps to further expand the number of Black-owned enterprises that provide supply chain services for our business in the United States. We also supported small and diverse vendors during the pandemic by shortening payment terms for those whose business with us is under $250,000. We prioritize partnerships with certified companies that share our dedication to improving the quality of patient care, including businesses that are:

- Minority-owned
- Women-owned
- Small or disadvantaged
- Service-disabled
- Veteran-owned
- LGBTQ-owned
- Disability-owned

We worked with 3,200 diverse suppliers and spent $599 million on the services of diverse suppliers.

“I’ve never been more impressed by our diverse network of suppliers than I was in 2020. Each came through to ensure our products were available wherever they were needed in the world. We are proud to partner with businesses with so much diversity of talent and perspective.”

Saken Khokhar, manager, Supplier Diversity
Sustainability in Packaging and Labeling

We develop packaging sustainability goals under the guidance of a global sustainability packaging and labeling steering committee. Our packaging and labeling practices include optimizing design, reducing waste and limiting emissions from shipping. In 2020, we conducted a global survey with customers to learn more about their sustainability practices and how we can work together to reduce waste and emissions. As a member of the Healthcare Plastics Recycling Council, we participated in its work to increase the recycling of plastics in clinical settings. This work has improved our ability to trace raw materials and learn how our customers dispose of the plastics used to safely deliver our products.

Boston Scientific packaging teams routinely share case studies to communicate the company’s support for sustainability and to share successful practices with our global teams. In 2020, we shared the following accomplishments:

- Packaging consolidation: By consolidating sterile barrier systems and sourcing more packaging materials locally in Clonmel, Ireland, the Neuromodulation team avoided using 755 kg of plastic and 1.03 metric tons of carbon emissions.
- Cold chain packaging redesign: By developing new packaging for SpaceOAR™ Hydrogel and SpaceOAR Vue™ Hydrogel that uses cold chain technology, we shipped more product per pallet and extended the time products can spend in transport.
- Packaging material efficiency: By shifting from two-pouch packaging to a single-pouch and thinner carton for the SYNERGY™ XD Bioabsorbable Polymer Stent, we reduced total shipping weight by 26.9 metric tons worldwide.

To reduce paper waste, we host an eLabeling website where customers can download Instructions for Use (IFU) for an increasing number of Boston Scientific products. Many IFU booklets that were previously printed and shipped with devices are now available online in multiple languages. By converting to electronic-only instructions for customers in Korea and Russia, we cut paper waste in the region by 35 metric tons in 2020.

2020 Packaging Sustainability Snapshot:

- 164 metric tons of packaging removed from waste stream
- 1,100 acres of forest saved
- 5,300 products diverted from landfills during development
- 697 pallet shipments avoided